

BCoR (C-10): sc-514576

BACKGROUND

Bcl-6, a transcriptional repressor, can promote or inhibit apoptosis depending on the cell type and also plays an important role in normal immune responses. Bcl-6 negatively regulates NF κ B expression, thereby inhibiting NF κ B-mediated cellular functions and is frequently found to be deregulated in non-Hodgkin's lymphoma. BCoR (Bcl-6 corepressor) is a 1,755 amino acid protein that associates with histone deacetylases (HDACs) to transcriptionally repress Bcl-6. With ubiquitous expression, BCoR is localized to the nucleus where it interacts with other proteins through its three ANK repeat domains. Mutations in the gene encoding BCoR result in microphthalmia with associated anomalies 2, also known as anophthalmia, which is characterized by variable features, such as renal aplasia, mental retardation, hypospadias, microencephaly and cryptorchidism. There are four isoforms of BCoR which are produced as a result of alternative splicing events.

CHROMOSOMAL LOCATION

Genetic locus: BCOR (human) mapping to Xp11.4.

SOURCE

BCoR (C-10) is a mouse monoclonal antibody raised against amino acids 1-300 mapping at the N-terminus of BCoR of human origin.

PRODUCT

Each vial contains 200 μ g IgG $_1$ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

BCoR (C-10) is available conjugated to agarose (sc-514576 AC), 500 μ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-514576 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-514576 PE), fluorescein (sc-514576 FITC), Alexa Fluor[®] 488 (sc-514576 AF488), Alexa Fluor[®] 546 (sc-514576 AF546), Alexa Fluor[®] 594 (sc-514576 AF594) or Alexa Fluor[®] 647 (sc-514576 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor[®] 680 (sc-514576 AF680) or Alexa Fluor[®] 790 (sc-514576 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor[®] is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

BCoR (C-10) is recommended for detection of BCoR of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for BCoR siRNA (h): sc-72635, BCoR shRNA Plasmid (h): sc-72635-SH and BCoR shRNA (h) Lentiviral Particles: sc-72635-V.


Molecular Weight of BCoR: 192 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200 or Y79 cell lysate: sc-2240.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



BCoR (C-10): sc-514576. Western blot analysis of BCoR expression in Y79 whole cell lysate. Detection reagent used: m-IgG κ BP-HRP: sc-516102.



BCoR (C-10): sc-514576. Western blot analysis of BCoR expression in HeLa whole cell lysate. Detection reagent used: m-IgG κ BP-HRP: sc-516102.

SELECT PRODUCT CITATIONS

- Kao, Y.C., et al. 2016. BCoR overexpression is a highly sensitive marker in round cell sarcomas with BCoR genetic abnormalities. *Am. J. Surg. Pathol.* 40: 1670-1678.
- Kao, Y.C., et al. 2017. BCoR upregulation in a poorly differentiated synovial sarcoma with SS18L1-SSX1 fusion-A pathologic and molecular pitfall. *Genes Chromosomes Cancer* 56: 296-302.
- Alholle, A., et al. 2018. Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTCl-SS18 gene fusion. *J. Pathol.* 245: 186-196.
- Mariño-Enriquez, A., et al. 2018. BCoR internal tandem duplication in high-grade uterine sarcomas. *Am. J. Surg. Pathol.* 42: 335-341.
- Argani, P., et al. 2018. Diffuse strong BCoR immunoreactivity is a sensitive and specific marker for clear cell sarcoma of the kidney (CCSK) in pediatric renal neoplasia. *Am. J. Surg. Pathol.* 42: 1128-1131.
- Banito, A., et al. 2018. The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. *Cancer Cell* 33: 527-541.
- Haberler, C., et al. 2019. Case of the month 1-2019: CNS high-grade neuroepithelial tumor with BCoR alteration. *Clin. Neuropathol.* 38: 4-7.
- Yau, D.T.W., et al. 2019. Bone sarcoma with EWSR1-NFATC2 fusion: sarcoma with varied morphology and amplification of fusion gene distinct from Ewing sarcoma. *Int. J. Surg. Pathol.* 27: 561-567.
- Cotzia, P., et al. 2019. Undifferentiated uterine sarcomas represent under-recognized high-grade endometrial stromal sarcomas. *Am. J. Surg. Pathol.* 43: 662-669.
- Ferris, S.P., et al. 2019. High-grade neuroepithelial tumor with BCoR exon 15 internal tandem duplication—a comprehensive clinical, radiographic, pathologic, and genomic analysis. *Brain Pathol.* E-published.

RESEARCH USE

For research use only, not for use in diagnostic procedures.